Question · asked by 1 review

Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs placebo: Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)

Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in major adverse events (eyelid ptosis, eyelid sensory disorder,… compared with placebo (moderate certainty).

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs placebo
Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) · glabellar lines
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in major adverse events (eyelid ptosis, eyelid sensory disorder,… compared with placebo (moderate certainty).
Botulinum toxin type A for facial wrinkles (2021) · Cochrane Headline outcomes only
RR 3.36 [0.88, 12.87]7 studies · 1294 participantsModerate

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Botulinum toxin type A for facial wrinkles
2021 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.